{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T12:51:41Z","timestamp":1791377501404,"version":"4.3.2"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"https:\/\/www.biomindlabs.com\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neuropsychopharmacol."],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1038\/s41386-025-02167-3","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:36:11Z","timestamp":1752539771000},"page":"1715-1723","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Safety and tolerability of multiple sublingual microdoses of 5-MeO-DMT in adults with moderate symptoms of depression and\/or anxiety: a randomized, double-blind, placebo-controlled study"],"prefix":"10.1038","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8850-2771","authenticated-orcid":false,"given":"Maria Beatriz","family":"Bistue Mill\u00f3n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Noguera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciana","family":"Vita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Zanino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego E.","family":"Kassuha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6368-3115","authenticated-orcid":false,"given":"Javier E.","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4076-3999","authenticated-orcid":false,"given":"Gabriela E.","family":"Feresin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"D\u00edaz-Dellavalle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena","family":"Orosco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Agustina","family":"Garc\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Diez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio G.","family":"Albarrac\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6005-5108","authenticated-orcid":false,"given":"Martin A.","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,15]]},"reference":[{"key":"2167_CR1","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1124\/pr.115.011478","volume":"68","author":"DE Nichols","year":"2016","unstructured":"Nichols DE. Psychedelics. Pharm Rev. 2016;68:264\u2013355.","journal-title":"Pharm Rev"},{"key":"2167_CR2","unstructured":"O\u2019Brien CP Drug use disorders and addiction. In: Hardman JG, Limbird LE, editors. Goodman & Gilman\u2019s: The Pharmacological Basis of Therapeutics. 10th ed. New York: McGraw-Hill; 2001. p. 574\u2013639."},{"key":"2167_CR3","doi-asserted-by":"publisher","first-page":"116715","DOI":"10.1016\/j.jns.2020.116715","volume":"411","author":"T Chi","year":"2020","unstructured":"Chi T, Gold JA. A review of emerging therapeutic potential of psychedelic drugs in the treatment of psychiatric illnesses. J Neurol Sci. 2020;411:116715.","journal-title":"J Neurol Sci"},{"key":"2167_CR4","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","volume":"384","author":"R Carhart-Harris","year":"2021","unstructured":"Carhart-Harris R, Giribaldi B, Watts R, Baker-Jones M, Murphy-Beiner A, Murphy R, et al. Trial of psilocybin versus escitalopram for depression. N. Engl J Med. 2021;384:1402\u201311.","journal-title":"N. Engl J Med"},{"key":"2167_CR5","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1080\/00952990.2018.1545024","volume":"45","author":"AK Davis","year":"2019","unstructured":"Davis AK, So S, Lancelotta R, Barsuglia JP, Griffiths RR. 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety. Am J Drug Alcohol Abus. 2019;45:161\u20139.","journal-title":"Am J Drug Alcohol Abus"},{"key":"2167_CR6","doi-asserted-by":"publisher","first-page":"760671","DOI":"10.3389\/fphar.2021.760671","volume":"12","author":"J Reckweg","year":"2021","unstructured":"Reckweg J, Mason NL, van Leeuwen C, Toennes SW, Terwey TH, Ramaekers JG. a phase 1, dose-ranging study to assess safety and psychoactive effects of a vaporized 5-methoxy-N, N-dimethyltryptamine formulation (GH001) in healthy volunteers. Front Pharm. 2021;12:760671.","journal-title":"Front Pharm"},{"key":"2167_CR7","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1111\/jnc.15587","volume":"162","author":"JT Reckweg","year":"2022","unstructured":"Reckweg JT, Uthaug MV, Szabo A, Davis AK, Lancelotta R, Mason NL, et al. The clinical pharmacology and potential therapeutic applications of 5\u2010methoxy\u2010N,N\u2010dimethyltryptamine (5\u2010MeO\u2010DMT). J Neurochem. 2022;162:128\u201346.","journal-title":"J Neurochem"},{"key":"2167_CR8","doi-asserted-by":"publisher","first-page":"1133414","DOI":"10.3389\/fpsyt.2023.1133414","volume":"14","author":"JT Reckweg","year":"2023","unstructured":"Reckweg JT, van Leeuwen CJ, Henquet C, van Amelsvoort T, Theunissen EL, Mason NL, et al. A phase 1\/2 trial to assess safety and efficacy of a vaporized 5-methoxy-N,N-dimethyltryptamine formulation (GH001) in patients with treatment-resistant depression. Front Psychiatry. 2023;14:1133414.","journal-title":"Front Psychiatry"},{"key":"2167_CR9","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1007\/s00213-011-2358-5","volume":"218","author":"RR Griffiths","year":"2011","unstructured":"Griffiths RR, Johnson MW, Richards WA, Richards BD, McCann U, Jesse R. Psilocybin occasioned mystical-type experiences: Immediate and persisting dose-related effects. Psychopharmacol (Berl). 2011;218:649\u201365.","journal-title":"Psychopharmacol (Berl)"},{"key":"2167_CR10","doi-asserted-by":"crossref","unstructured":"Polito V, Stevenson RJ. A systematic study of microdosing psychedelics. PLoS One. 2019;14:e0211023.","DOI":"10.1371\/journal.pone.0211023"},{"key":"2167_CR11","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1080\/02791072.2019.1593561","volume":"51","author":"J Fadiman","year":"2019","unstructured":"Fadiman J, Korb S. Might microdosing psychedelics be safe and beneficial? an initial exploration. J Psychoact Drugs. 2019;51:118\u201322.","journal-title":"J Psychoact Drugs"},{"key":"2167_CR12","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1007\/s00213-018-5106-2","volume":"236","author":"T Anderson","year":"2019","unstructured":"Anderson T, Petranker R, Rosenbaum D, Weissman CR, Dinh-Williams LA, Hui K, et al. Microdosing psychedelics: personality, mental health, and creativity differences in microdosers. Psychopharmacol (Berl). 2019;236:731\u201340.","journal-title":"Psychopharmacol (Berl)"},{"key":"2167_CR13","doi-asserted-by":"publisher","first-page":"32067","DOI":"10.1021\/acsomega.0c05099","volume":"5","author":"AM Sherwood","year":"2020","unstructured":"Sherwood AM, Claveau R, Lancelotta R, Kaylo KW, Lenoch K. Synthesis and characterization of 5-MeO-DMT succinate for clinical use. ACS Omega. 2020;5:32067\u201375.","journal-title":"ACS Omega"},{"key":"2167_CR14","doi-asserted-by":"publisher","first-page":"659","DOI":"10.2174\/138920010794233495","volume":"11","author":"HW Shen","year":"2011","unstructured":"Shen HW, Jiang XL, C. Winter J, Yu AM. Psychedelic 5-methoxy-N,N-dimethyltryptamine: metabolism, pharmacokinetics, drug interactions, and pharmacological actions. Curr Drug Metab. 2011;11:659\u201366.","journal-title":"Curr Drug Metab"},{"key":"2167_CR15","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1556\/2054.2020.00123","volume":"4","author":"MV Uthaug","year":"2020","unstructured":"Uthaug MV, Lancelotta R, Ortiz Bernal AM, Davis AK, Ramaekers JG. A comparison of reactivation experiences following vaporization and intramuscular injection (IM) of synthetic 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in a naturalistic setting. J Psychedelic Stud. 2020;4:104\u201313.","journal-title":"J Psychedelic Stud"},{"key":"2167_CR16","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.1007\/s00213-019-05236-w","volume":"236","author":"MV Uthaug","year":"2019","unstructured":"Uthaug MV, Lancelotta R, van Oorsouw K, Kuypers KPC, Mason N, Rak J, et al. A single inhalation of vapor from dried toad secretion containing 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in a naturalistic setting is related to sustained enhancement of satisfaction with life, mindfulness-related capacities, and a decrement of psyc. Psychopharmacol (Berl). 2019;236:2653\u201366.","journal-title":"Psychopharmacol (Berl)"},{"key":"2167_CR17","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s40261-024-01357-z","volume":"44","author":"J Yoon","year":"2024","unstructured":"Yoon J, Sharma V, Harada A. Safety, tolerability, and pharmacokinetics of oral BI 1358894 in Healthy Japanese Male Volunteers. Clin Drug Investig. 2024;44:319\u201328.","journal-title":"Clin Drug Investig"},{"key":"2167_CR18","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1038\/s41386-023-01609-0","volume":"48","author":"I Straumann","year":"2023","unstructured":"Straumann I, Ley L, Holze F, Becker AM, Klaiber A, Wey K, et al. Acute effects of MDMA and LSD co-administration in a double-blind placebo-controlled study in healthy participants. Neuropsychopharmacology. 2023;48:1840\u20138.","journal-title":"Neuropsychopharmacology"},{"key":"2167_CR19","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1111\/jnc.15544","volume":"162","author":"HN Saeger","year":"2022","unstructured":"Saeger HN, Olson DE. Psychedelic-inspired approaches for treating neurodegenerative disorders. J Neurochem. 2022;162:109\u201327.","journal-title":"J Neurochem"},{"key":"2167_CR20","doi-asserted-by":"crossref","unstructured":"Mastinu A, Anyanwu M, Carone M, Abate G, Bonini SA, Peron G, et al. The bright side of psychedelics: latest advances and challenges in neuropharmacology. Int J Mol Sci. 2023;24:1329.","DOI":"10.3390\/ijms24021329"},{"key":"2167_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41398-022-02039-0","volume":"12","author":"Cavanna","year":"2022","unstructured":"Cavanna, Muller F, de la Fuente LA S, Zamberlan F, Palmucci M, Janeckova L, et al. Microdosing with psilocybin mushrooms: a double-blind placebo-controlled study. Transl Psychiatry. 2022;12:1\u201311.","journal-title":"Transl Psychiatry"},{"key":"2167_CR22","first-page":"1","volume":"21204","author":"ST Aaronson","year":"2024","unstructured":"Aaronson ST, Van Der Vaart A, Miller T, Lapratt J, Swartz K, Shoultz A, et al. Single-dose synthetic psilocybin with psychotherapy for treatment-resistant bipolar type II major depressive episodes: a nonrandomized controlled trial. JAMA Psychiatry. 2024;21204:1\u20138.","journal-title":"JAMA Psychiatry"},{"key":"2167_CR23","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1038\/s41386-023-01607-2","volume":"48","author":"L Ley","year":"2023","unstructured":"Ley L, Holze F, Arikci D, Becker AM, Straumann I, Klaiber A, et al. Comparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participants. Neuropsychopharmacology. 2023;48:1659\u201367.","journal-title":"Neuropsychopharmacology"},{"key":"2167_CR24","first-page":"1","volume":"14","author":"E James","year":"2023","unstructured":"James E, Erritzoe D, Benway T, Joel Z, Timmermann C, Good M, et al. Safety, tolerability, pharmacodynamic and wellbeing effects of SPL026 (dimethyltryptamine fumarate) in healthy participants: a randomized, placebo-controlled phase 1 trial. Front Psychiatry. 2023;14:1\u201314.","journal-title":"Front Psychiatry"},{"key":"2167_CR25","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1080\/02791072.2020.1737763","volume":"52","author":"RL Lancelotta","year":"2020","unstructured":"Lancelotta RL, Davis AK. Use of Benefit Enhancement Strategies among 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) Users: Associations with Mystical, Challenging, and Enduring Effects. J Psychoact Drugs. 2020;52:273\u201381.","journal-title":"J Psychoact Drugs"},{"key":"2167_CR26","doi-asserted-by":"crossref","unstructured":"Holze F, Singh N, Liechti ME, D\u2019Souza DC. Serotonergic Psychedelics: A Comparative Review of Efficacy, Safety, Pharmacokinetics, and Binding Profile. Vol. 9, Biological Psychiatry: Cognitive Neuroscience and Neuroimaging. Elsevier Inc.; 2024. p. 472\u201389.","DOI":"10.1016\/j.bpsc.2024.01.007"},{"key":"2167_CR27","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1007\/s00213-021-05978-6","volume":"239","author":"F Holze","year":"2022","unstructured":"Holze F, Caluori T, Vizeli P, Liechti M. Safety pharmacology of acute LSD administration in healthy subjects. Psychopharmacology. 2022;239:1893\u2013905.","journal-title":"Psychopharmacology"},{"key":"2167_CR28","unstructured":"Introductory Guide for Standardised MedDRA Queries (SMQs) Version 27.0. 2024.001126."},{"key":"2167_CR29","first-page":"515","volume":"37","author":"LL Olabarriet.a","year":"2015","unstructured":"Olabarriet.a LL, Rivera D, Galarza-Del-Angel J, Garza MT, Saracho CP, Rodr\u00edguez W, et al. Verbal fluency tests: Normative data for the Latin American Spanish speaking adult population. NeuroRehabilitation. 2015;37:515\u201361.","journal-title":"NeuroRehabilitation"},{"key":"2167_CR30","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1080\/23279095.2015.1092150","volume":"23","author":"S Vanotti","year":"2016","unstructured":"Vanotti S, Eizaguirre MB, Cores EV, Yastremis C, Garcea O, Salgado P, et al. Validation of the PASAT in Argentina. Appl Neuropsychol Adult. 2016;23:379\u201383.","journal-title":"Appl Neuropsychol Adult"},{"key":"2167_CR31","unstructured":"Wechsler D. WISC-V: Technical and interpretive manual. Bloomington, MN: NCS Pearson 2015."},{"key":"2167_CR32","doi-asserted-by":"crossref","unstructured":"Daly I, Williams D, Hwang F, Kirke A, Miranda ER, Nasuto SJ. Electroencephalography reflects the activity of sub-cortical brain regions during approach-withdrawal behaviour while listening to music. Sci Rep. 2019;9:9415.","DOI":"10.1038\/s41598-019-45105-2"},{"key":"2167_CR33","doi-asserted-by":"crossref","unstructured":"Hohaia W, Saurels BW, Johnston A, Yarrow K, Arnold DH. Occipital alpha-band brain waves when the eyes are closed are shaped by ongoing visual processes. Sci Rep. 2022;12:1194.","DOI":"10.1038\/s41598-022-05289-6"},{"key":"2167_CR34","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1021\/acsptsci.0c00099","volume":"4","author":"NRPW Hutten","year":"2021","unstructured":"Hutten NRPW, Mason NL, Dolder PC, Theunissen EL, Holze F, Liechti ME, et al. Low doses of LSD acutely increase BDNF blood plasma levels in healthy volunteers. ACS Pharm Transl Sci. 2021;4:461\u20136.","journal-title":"ACS Pharm Transl Sci"},{"key":"2167_CR35","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1002\/bmc.1657","volume":"26","author":"EH McIlhenny","year":"2012","unstructured":"McIlhenny EH, Riba J, Barbanoj MJ, Strassman R, Barker SA. Methodology for determining major constituents of ayahuasca and their metabolites in blood. Biomed Chromatogr. 2012;26:301\u201313.","journal-title":"Biomed Chromatogr"},{"key":"2167_CR36","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s13318-023-00822-y","volume":"48","author":"M Good","year":"2023","unstructured":"Good M, Joel Z, Benway T, Routledge C, Timmermann C, Erritzoe D, et al. Pharmacokinetics of N,N-dimethyltryptamine in Humans. Eur J Drug Metab Pharmacokinet. 2023;48:311\u201327.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"2167_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fnhum.2016.00269","volume":"10","author":"MM Nour","year":"2016","unstructured":"Nour MM, Evans L, Nutt D, Carhart-Harris RL. Ego-dissolution and psychedelics: validation of the ego-dissolution inventory (EDI). Front Hum Neurosci. 2016;10:1\u201313.","journal-title":"Front Hum Neurosci"},{"key":"2167_CR38","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1177\/0269881115609019","volume":"29","author":"FS Barrett","year":"2015","unstructured":"Barrett FS, Johnson MW, Griffiths RR. Validation of the revised mystical experience questionnaire with psilocybin. J Psychopharmacol. 2015;29:1182\u201390.","journal-title":"J Psychopharmacol"},{"key":"2167_CR39","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.paid.2017.06.004","volume":"117","author":"FS Barrett","year":"2017","unstructured":"Barrett FS, Matthew PB, Leoutsakos J-MS. Neuroticism is associated with challenging experiences with psilocybin mushrooms. Pers Individ Dif. 2017;117:155\u201360.","journal-title":"Pers Individ Dif"},{"key":"2167_CR40","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1177\/02698811241246857","volume":"38","author":"JJ Rucker","year":"2024","unstructured":"Rucker JJ, Roberts C, Seynaeve M, Young AH, Suttle B, Yamamoto T, et al. Phase 1, placebo-controlled, single ascending dose trial to evaluate the safety, pharmacokinetics and effect on altered states of consciousness of intranasal BPL-003 (5-methoxy-N,N-dimethyltryptamine benzoate) in healthy participants. J Psychopharmacol. 2024;38:712\u201323.","journal-title":"J Psychopharmacol"}],"container-title":["Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41386-025-02167-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41386-025-02167-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41386-025-02167-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T08:05:48Z","timestamp":1757923548000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41386-025-02167-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,15]]},"references-count":40,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["2167"],"URL":"https:\/\/doi.org\/10.1038\/s41386-025-02167-3","relation":{},"ISSN":["0893-133X","1740-634X"],"issn-type":[{"value":"0893-133X","type":"print"},{"value":"1740-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,15]]},"assertion":[{"value":"11 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"During the study, PD-D was the Chief Scientific Officer of Biomind Labs Inc. MB was the Clinical Advisor of Biomind Labs Inc. during the study. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}